DA 125

Subscribe to Selected New Research on DA 125

12 relevant articles (0 outcomes, 4 trials/studies) found for this Bio-Agent

Description: structure in first source

Also Known As:

DA-125; beta-Alanine, 2-(4-((2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl ester, hydrochloride, (2S-cis)-

Bio-Agent Context: Research Results

Experts

1.	Park, Eun-Jung: 1 article (12/2005)
2.	Hong, Ji-Young: 1 article (12/2005)
3.	Lee, Sang Kook: 1 article (12/2005)
4.	Kim, Won Bae: 1 article (12/2005)
5.	Park, Hyen Joo: 1 article (12/2005)
6.	Min, Hye-Young: 1 article (12/2005)
7.	Kim, Soon Hoe: 1 article (12/2005)
8.	Chung, Hwa-Jin: 1 article (12/2005)

Related Diseases

1.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/1999 - "The purpose of this phase II study was to evaluate the efficacy and toxicity of DA-125 in patients with non-small-cell lung cancer (NSCLC). " 01/01/1999 - "A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer." Order ALL the reference details at left...
2.	Hepatocellular Carcinoma (Hepatoma) 06/01/2001 - "In the present study, we compared the cytotoxicity of DA-125 with that of doxorubicin in H4IIE rat hepatoma cells and investigated the mechanistic basis. " Order ALL the reference details at left...
3.	Fibrosarcoma 12/19/2005 - "Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases." 12/19/2005 - "In this study, we examined the influence of DA-125, a new anthracyclin analog, on the gene expression of MMPs (MMP-2, MMP-9 and MT1-MMP), tissue inhibitor of metalloproteinases (TIMP-1 and TIMP-2) and in vitro invasiveness of human fibrosarcoma cells. " Order ALL the reference details at left...
4.	Adenocarcinoma 09/01/1997 - "Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin." 09/01/1997 - "The study was undertaken to investigate the antitumor activity of DA-125, a promising new analogue of adriamycin (ADM) containing fluorine, against human gastric and pulmonary adenocarcinoma cell lines and their sublines resistant to ADM and cisplatin (CDDP) by MTT assay. " Order ALL the reference details at left...
5.	Neoplasms (Cancer) 12/19/2005 - "These data, therefore, provide direct evidence for the role of DA-125 as a potential cancer chemotherapeutic agent, which can markedly inhibit the invasive capacity of malignant cells. " 12/19/2005 - "In addition, DA-125 inhibited the invasion, motility and cell migration, and colony formation of tumor cells. " 06/01/1998 - "Single dose of DA-125, 20 (n = 3), 40 (n = 3), 60 (n = 3), 80 (n = 6), or 100 (n = 6) mg/m2 body surface area, was administered intravenously in 5 min to 21 patients with various types of cancer as phase I clinical trial. " 01/01/1997 - "Cellular uptake and antitumor activity of the new anthracycline analog DA-125 in human cancer cell lines." 01/01/2004 - "DA-125, a novel derivative of adriamycin, is known for its anti-cancer activity. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	ADM protocol
3.	Matrix Metalloproteinases
4.	Tissue Inhibitor of Metalloproteinases (TIMP)
5.	Fluorine
6.	Cisplatin (Platino)
7.	Uranyl Nitrate
8.	Desoxycorticosterone (DOCA)
9.	Alloxan
10.	tranilast (N 5')

Best Treatments:
Research Summary Report
on Small Cell Lung Carcinoma

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1101 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>